These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2612554)

  • 21. Acetylation phenotypes and bladder cancer.
    Hanke J; Krajewska B
    J Occup Med; 1990 Sep; 32(9):917-8. PubMed ID: 2074519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylation of dapsone by human whole blood.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM; Gharaibeh NS
    Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):18-22. PubMed ID: 8444513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acetylator phenotype in Iraqi patients with atopic dermatitis.
    Najim RA; Al-Waiz MM; Al-Razzuqi RA
    Dermatol Online J; 2006 Dec; 12(7):1. PubMed ID: 17459287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls].
    Sone M
    Hinyokika Kiyo; 1986 Aug; 32(8):1085-92. PubMed ID: 3788733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP1A2 activity as a risk factor for bladder cancer.
    Lee SW; Jang IJ; Shin SG; Lee KH; Yim DS; Kim SW; Oh SJ; Lee SH
    J Korean Med Sci; 1994 Dec; 9(6):482-9. PubMed ID: 7786445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P
    Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphic N-acetylation capacity in lung cancer.
    Philip PA; Fitzgerald DL; Cartwright RA; Peake MD; Rogers HJ
    Carcinogenesis; 1988 Mar; 9(3):491-3. PubMed ID: 3345587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers.
    Hayes RB; Bi W; Rothman N; Broly F; Caporaso N; Feng P; You X; Yin S; Woosley RL; Meyer UA
    Carcinogenesis; 1993 Apr; 14(4):675-8. PubMed ID: 8472331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus.
    Morris RJ; Freed CR; Kohler PF
    Arthritis Rheum; 1979 Jul; 22(7):777-80. PubMed ID: 454504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
    Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
    Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetylation polymorphism of caffeine in a Japanese population.
    Hashiguchi M; Ebihara A
    Clin Pharmacol Ther; 1992 Sep; 52(3):274-6. PubMed ID: 1526084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
    Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-acetyltransferase polymorphism in patients with Behçet's disease.
    Aynacioglu AS; Bozkurt A; Nacak M; Kortunay S; Tunc R; Dincel A; Kayaalp SO
    Eur J Clin Pharmacol; 2001 Nov; 57(9):659-62. PubMed ID: 11791896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations.
    Sohn DR; Kusaka M; Shin SG; Jang IJ; Chiba K; Ishizaki T
    Ther Drug Monit; 1992 Jun; 14(3):184-9. PubMed ID: 1412602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
    Bluhm RE; Adedoyin A; McCarver DG; Branch RA
    Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetylator phenotype in relation to age and gender in the Baltimore Longitudinal Study of Aging.
    Korrapati MR; Sorkin JD; Andres R; Muller DC; Loi CM; Vesell ES; Vestal RE
    J Clin Pharmacol; 1997 Feb; 37(2):83-91. PubMed ID: 9055133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association of the slow acetylator phenotype with bladder cancer.
    Evans DA; Eze LC; Whibley EJ
    J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population.
    Mommsen S; Barfod NM; Aagaard J
    Carcinogenesis; 1985 Feb; 6(2):199-201. PubMed ID: 3971485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.